John Young is the Group President, Chief Business Officer at Pfizer Inc., and is a member of the Company’s Executive Leadership Team.
As Chief Business Officer, John leads a division that integrates all Strategy, Consulting, Business Development, Business Assessment, Portfolio & Decision Analysis, and the Patient & Health Impact reimbursement and access team.
Prior to this role, John was the Group President of Pfizer Innovative Health, which included six business units: Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease, Vaccines and Consumer Healthcare; each business unit focused on developing innovative medicines and vaccines to make a meaningful difference to patients impacted by diseases with significant unmet need. John was also responsible for these businesses in Emerging Markets focused on increasing access to Pfizer’s innovative medicines to people across developing countries in Latin America, Asia, Africa and the Middle East.
Previously, John was the Group President for Pfizer Essential Health where he oversaw a broad portfolio of more than 600 products with a global reach in 160 countries. A scientist by training, John has more than 30 years of experience with Pfizer and has held a number of senior positions across the organization.
John is a member of the Board of Directors of the Consumer Healthcare Joint Venture with GlaxoSmithKline plc, and also Johnson Controls International (JCI). He serves on the Board of BIO (Biotechnology Innovation Organization) and as a member of the UK Government bioscience working group, the Life Sciences Council.
John holds a BSc in Biological Science from Glasgow University and an MBA from Strathclyde Graduate Business School. He is married with three daughters.